CCL3 and plasma cell myeloma: To reliably identify associations between blood immune marker levels of MCP-3, MIP-1α, FGF-2, VEGF, fractalkine, and TGF-α and the future risk of multiple myeloma, we performed a case–control study using prospective samples from the Janus Serum Bank in Norway.